Domača stranSTRO • NASDAQ
add
Sutro Biopharma Inc
1,79 $
Po zaprtju:(0,49 %)−0,0087
1,78 $
Konec trgovanja: 13. jan., 16:30:00 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
1,85 $
Dnevni razpon
1,71 $ - 1,84 $
Letni razpon
1,70 $ - 6,13 $
Tržna kapitalizacija
147,60 mio. USD
Povprečni obseg
1,22 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 8,52 mio. | −49,66 % |
Stroški poslovanja | 14,33 mio. | −6,14 % |
Čisti dohodek | −48,79 mio. | 1,01 % |
Čista dobičkovnost prihodkov | −572,62 | −96,63 % |
Earnings per share | −0,50 | 38,49 % |
EBITDA | −66,12 mio. | −56,40 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 388,25 mio. | 9,32 % |
Skupna sredstva | 451,83 mio. | 4,66 % |
Skupne obveznosti | 340,61 mio. | 6,65 % |
Celoten lastniški kapital | 111,22 mio. | — |
Shares outstanding | 82,46 mio. | — |
Razmerje P/B | 1,37 | — |
Donosnost sredstev | −36,09 % | — |
Donosnost kapitala | −107,88 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −48,79 mio. | 1,01 % |
Denar iz dejavnosti | −64,52 mio. | −92,57 % |
Denar iz naložb | 147,29 mio. | 229,18 % |
Denar iz financiranja | 1,02 mio. | 117,72 % |
Neto sprememba denarnih sredstev | 83,79 mio. | 154,67 % |
Prost denarni tok | −39,84 mio. | −81,30 % |
Vizitka
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
Datum ustanovitve
2003
Sedež organizacije
Spletno mesto
Zaposleni
306
